Modality
Vaccine
MOA
PI3Ki
Target
FLT3
Pathway
DDR
CLL
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
~Jul 2023
→ ~Oct 2024
NDA/BLA
Jan 2025
→ Mar 2026
NDA/BLACurrent
NCT05413595
444 pts·CLL
2025-01→2026-03·Not yet recruiting
444 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-064w agoPh3 Readout· CLL
Trial Timeline
2025Q2Q3Q42026
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-03-06 · 4w ago
CLL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05413595 | NDA/BLA | CLL | Not yet recr... | 444 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 |